グラクソ・スミスクライン

 GSKのチャート


 GSKの企業情報

symbol GSK
会社名 GlaxoSmithKline Plc (グラクソ・スミスクライン)
分野(sector)   
産業(industry)   
業種 医薬品   医療関連(Health Care)
概要 グラクソ・スミスクライン(GlaxoSmithKline plc)は医療グループであり、ワクチン、市販薬(OTC)及び健康製品等の医薬品の作成、発見、開発、製造及び販売に従事する。同社は主に呼吸器、抗ウイルス、中枢神経系、心血管と泌尿生殖器、代謝、抗菌、腫瘍と嘔吐、皮膚、希少疾患、免疫・炎症、ワクチン及びヒト免疫不全ウイルス(HIV)等の治療分野向けに医薬品を提供している。同社は主に医薬品事業、ワクチン事業、およびコンシューマーヘルスケア事業の3事業区分により構成される。平成24年1月31日、同社は米国とカナダにおけるブランドをPrestige Brands Holdingsに売却完了した。同年8月、同社はHuman Genome Sciencesを買収した。平成25年1月30日、GSKは同社における持ち分の29.3%を追加買収した。  グラクソ・スミスクラインはイギリスの製薬メ―カ―。呼吸器、抗ウイルス、中枢神経、心臓血管、泌尿生殖器、がん、ワクチン、HIV分野で医療用医薬品を展開。主要製品は、鼻炎治療薬、肺疾患治療薬、抗血栓症薬、がん治療薬、抗HIV薬、ジフテリア・インフルエンザワクチンなど。オ―ラルケア製品、禁煙補助薬、市販薬、栄養補助製品などヘルスケア製品も提供。  GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
本社所在地 980 Great West Road Brentford Middlesex TW8 9GS GBR
代表者氏名 Emma Walmsley
代表者役職名 Chief Executive Officer Executive Director
電話番号 +44 20-8047-5000
設立年月日 36495
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 95490人
url www.gsk.com
nasdaq_url
adr_tso
EBITDA (百万ドル) 12929.04000
終値(lastsale)
時価総額(marketcap)
時価総額 (百万ドル) 103966.30000
売上高 (百万ドル) 40178.07000
企業価値(EV) (百万ドル) 132783.55500
当期純利益 (百万ドル) 4885.87000
決算概要 BRIEF: For the fiscal year ended 31 December 2018 GlaxoSmithKline plc (ADR) revenues increased 2% to £30.82B. Net income before extraordinary items increased 44% to £3.75B. Revenues reflect Vaccines segment increase of 14% to £5.89B US segment increase of 6% to £11.98B. Net income benefited from Consumer Healthcare segment income increase from £1.37B to £5.74B Unallocated segment loss decrease of 23% to £3.72B. Dividend per share remained flat at £0.80.

 GSKのテクニカル分析


 GSKのニュース

   Global Perinatal Infections Market Analysis By Size, Growth Rate, Share, Trends, Key Players, COVID-19 Impact 2020-2027||Arbor Pharmaceuticals, Par Pharmaceutical, Mylan N.V., GlaxoSmithKline Plc., Novartis AG  2020/10/10 15:56:06 OpenPR
“Global Perinatal Infections Market–Industry Trends and Forecast to 2027” New Research Report Added to Databridgemarketresearch.com database. The report width Of pages : 350 Figures: 60 And Tables: 220 in it.The global Perinatal Infections market is highly fragmented and the
   Global Asthma and COPD Smart Inhalers Markets Report 2020 with Profiles of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Teva Pharma - ResearchAndMarkets.com  2020/10/09 09:39:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Smart Inhalers: Global Markets" report has been added to ResearchAndMarkets.com's offering. The current report offers a comprehensive picture of the smart inhalers market. Smart inhalers prescribed for the treatment of asthma and COPD are included in the scope of the study. The global market's growth is attributed to factors such as the growing prevalence of respiratory diseases, a rise in the world's geriatric population, growing collaboration between pharma and d
   GlaxoSmithKline: An Unusual Defensive Healthcare Play (NYSE:GSK)  2020/10/09 03:26:53 Seeking Alpha
GlaxoSmithKline is in one of its best positions in recent history, with strong financials, a very diversified business and potential for big upside.
   Pazopanib Market To Set Outstanding Growth In Key Regions By 2025 Featuring Renowned Key Players | GlaxoSmithKline, Novartis  2020/10/08 15:20:38 OpenPR
The Pazopanib market 2020 report analyses global acceptance of trends, future growth potential, key drivers, limitations, opportunities, and best practices that are taken place in market. The report also examines growth potential, market sizes and revenue forecasts (2020-2025)across different regions
   Human Rotavirus Vaccine Market Rapidly Growing in Healthcare Sector by 2020-2027 with Prominent Players: Merck & Co.Inc., Bharat Biotech, GlaxoSmithKline plc.  2020/10/08 13:23:04 OpenPR
Rotavirus vaccine is a vaccine used to protect against rotavirus infections, which are the leading cause of severe diarrhea among young children. The vaccines prevent 15–34% of severe diarrhea in the developing world and 37–96% of severe diarrhea in the
   GSK and Sanofi in 'advanced discussions' with EU over Covid-19 vaccine  2020/08/03 11:22:00 Evening Standard
Drugs giants GlaxoSmithKline and Sanofi today neared the completed a trio of key agreements to supply their Covid-19 vaccine, amid discussions with the EU. The pair said they are in “advanced discussions” with the European bloc to supply 300 million doses of their candidate, which uses Sanofi's recombinant protein-based technology combined with GSK's pandemic adjuvant system.
   GlaxoSmithKline PLC Total Voting Rights  2020/08/03 10:31:00 ADVFN UK
GlaxoSmithKline PLC 03 August 2020 GlaxoSmithKline plc Total Voting Rights and Capital In conformity with the Financial Conduct…
   GlaxoSmithKline und Sanofi beliefern EU mit COVID-19-Impfstoff - Aktien in Grün  2020/08/03 08:09:00 Finanzen CH
Wie das britische Pharmaunternehmen mitteilte, basiert der Impfstoffkandidat auf Sanofis Technologie zur Herstellung eines Grippeimpfstoffs sowie auf der Pandemie-Adjuvans-Technologie von GSK . Produziert würden die…
   Sanofi, GSK to supply 300M COVID-19 vaccine doses to EU (NASDAQ:SNY)  2020/08/03 07:38:16 Seeking Alpha
Sanofi (NASDAQ:SNY) and development partner GlaxoSmithKline (NYSE:GSK) are in advanced discussions with the European Union (EU) to supply up to 300M doses
   The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings  2020/08/02 15:08:50 Benzinga
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in, with big pharma tie-ups flaunting positive tidings. In the biggest ever coronavirus funding deal, the Sanofi SA (NASDAQ: SNY ) GlaxoSmithKline plc (NYSE: GSK ) won a joint $2.1 billion U.S. federal funding award. Here're the key catalysts for the unfolding week: Conferences 72nd National Hemophilia Foundation's Annual Bleeding Disorders Meeting 2020 (virtual meeting): Aug. 1-8 PDUFA Dates FDA is scheduled to rule on DBV TECHNOLOGIE/S' ADR (NASDAQ: DBVT ) Viaskin peanut allergy patch Wednesday. However, cancellation of the Adcom meeting scheduled May 15 has poured cold water on the prospects of an approval coming through. Trevena Inc (NASDAQ: TRVN ) has a tryst with the FDA Friday, with respect to the NDA for its pain drug oleceridine, which was once rejected by the agency on the premise of inadequacy of clinical data.

 関連キーワード  (医薬品 米国株 グラクソ・スミスクライン GSK )

 twitter  (公式ツイッターやCEOツイッターなど)

GSK動画